

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: www.sunpharma.com  
CIN: L24230GJ1993PLC019050



January 30, 2021

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051  
**NSE Code – SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**BSE Code – 524715**

Dear Sirs,

**Sub: Submission of Newspaper advertisement under Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published an advertisement giving Notice of the Record Date for the purpose of payment of Interim Dividend for the financial year 2020-21, in all the editions of Financial Express dated January 30, 2021 and in Ahmedabad Edition (Gujarati Language) of Financial Express dated January 30, 2021.

We are enclosing herewith copy of the advertisement published in the following newspapers:

1. Financial Express dated January 30, 2021– Mumbai Edition
2. Financial Express dated January 30, 2021– Ahmedabad Edition
3. Financial Express dated January 30, 2021– Ahmedabad Edition (Gujarati Language)

This is for your information and dissemination.

Thanking you,

Yours faithfully,

**For Sun Pharmaceutical Industries Limited**

Ashok  
Indulal  
Bhuta  
Digitally signed  
by Ashok Indulal  
Bhuta  
Date: 2021.01.30  
15:03:59+05'30'

**Ashok I. Bhuta**

**Sr. GM - Secretarial &  
Compliance Officer**

**Encl: As above**

**BENGAL ASSAM COMPANY LIMITED**  
 Regd. Office: 17, Council Chamber, Kolkata - 700 001  
 CIN : L67120WB1947PLC221402  
 Website: www.bengalassam.com  
 Email: dsawain@gmail.com  
 Tel: 033-22486181, Fax: 033-22481641

**NOTICE**  
 Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, 8th February, 2021 inter-alia, for approval of the Unaudited Financial Results of the Company for the third quarter ended 31st December, 2020.

This information is also available on the website of the Company i.e. www.bengalassam.com and the website of BSE Limited i.e. www.bseindia.com, where the Company's equity shares are listed.

For Bengal & Assam Company Limited  
 Dillip Kumar Swain  
 Company Secretary  
 Place : New Delhi  
 Date : 29.01.2021

**Sun Pharmaceutical Industries Limited**  
 Regd. Office: SPARC, Tandajia, Vadodara - 390012, Gujarat, INDIA  
 Corporate Office: Sun House, Plot No. 201 B/1,  
 Western Express Highway, Goregaon (E), Mumbai - 400063  
 Tel: +91 22 4324 4324 CIN: L24230GJ1993PLC019050  
 Website: www.sunpharma.com

**Notice of Record Date for Interim Dividend**  
 Notice is hereby given, that the Company has, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and any other applicable regulations, fixed, Wednesday, February 10, 2021 as the Record Date for the purpose of determining eligible shareholders entitled to receive Interim Dividend of Rs. 5.50/- (Rupees Five and paise fifty only) per equity share of Re. 1/- each for the financial year 2020-21 as declared by the Board of Directors of the Company at its meeting held on Friday, January 29, 2021. The payment of the Interim Dividend, would be made to the eligible shareholders on or before February 19, 2021.

The Equity Shareholders who wish to waive / forgo their right to receive the Interim Dividend shall send the irrevocable instruction waiving / forgoing dividend in the form prescribed by the Board of Directors of the Company so as to reach the Company on or before the Record Date i.e. Wednesday, February 10, 2021.

The form prescribed by the Board of Directors of the Company for waiving / forgoing the right to receive Dividend is available for download on the Company's website www.sunpharma.com under section "Investor - Shareholder's Information- Statutory Communications" or can also be obtained from the Company's Registrar and Share Transfer Agent, Link Intime India Private Limited.

The instruction by a Shareholder to the Company for waiving/ forgoing the right to receive dividend for any year is purely voluntary on the part of the Shareholder. There is no interference with a Shareholder's Right to receive the dividend, if he does not wish to waive/forgo his right to receive the dividend. No action is required on the part of Shareholder who wishes to receive dividends as usual, such Shareholder will automatically receive dividend as declared.

For Sun Pharmaceutical Industries Limited  
 Sd/-  
 Ashok I. Bhuta  
 Compliance Officer  
 Place : Mumbai  
 Date : January 29, 2021

**GOKALDAS EXPORTS LIMITED**  
 Corporate Identification Number (CIN): L18101KA2004PLC033475  
 Regd. Office : No. 25, 2nd Cross, 3rd Main, Industrial Suburb, Yeshwanthpur, Bangalore-560022.  
 Tel: +91 80 68951000 Fax: +91 80 68951001 E-mail: gokex@gokaldasexports.com Website: www.gokaldasexports.com

**Statement of unaudited Standalone and Consolidated Ind AS Financial Results for the quarter and nine months ended December 31, 2020**  
 (Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015) (in Rs. Lakh, except earnings per share)

Sl. No.	Particulars	Standalone					Consolidated						
		Quarter Ended		9 months Ended		Year Ended	Quarter Ended		9 months Ended		Year Ended		
		Dec 31, 2020	Sep 30, 2020	Dec 31, 2019	Dec 31, 2019	March 31, 2020	Dec 31, 2020	Sep 30, 2020	Dec 31, 2019	Dec 31, 2019	March 31, 2020		
1	Total Income	27,019.66	34,467.80	32,744.18	85,206.20	1,03,980.06	1,38,410.77	27,076.23	34,489.42	32,852.28	85,295.28	1,04,213.73	1,38,722.62
2	Net profit/(Loss) before tax and exceptional items	593.30	851.17	855.93	1,055.15	2,224.85	1,242.00	604.68	866.51	955.19	1,045.22	2,129.12	1,044.77
3	Net profit/(Loss) before tax and after exceptional items	593.30	851.17	(1,436.13)	1,055.15	2,537.57	3,235.94	604.68	866.51	(1,336.87)	1,045.22	2,441.84	3,038.71
4	Net Profit/(Loss) after tax and exceptional items	593.30	851.17	(1,436.13)	1,055.15	2,537.57	3,235.94	604.68	866.51	(1,336.87)	1,045.22	2,441.84	3,038.71
5	Total Comprehensive Income for the period / year	1,579.52	2,175.98	(1,405.09)	4,456.52	1,358.08	(364.90)	1,591.65	2,192.07	(1,305.83)	4,448.84	1,262.35	(559.89)
6	Paid-up equity share capital (Face value Rs. 5 each, fully paid up)	2,144.78	2,141.28	2,141.03	2,144.78	2,141.03	2,141.28	2,144.78	2,141.28	2,141.03	2,144.78	2,141.03	2,141.28
7	Other equity as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	20,725.05	-	-	-	-	-	20,520.05
8	Earnings Per Equity Share (EPS)												
	Basic :	1.38	1.99	(3.35)	2.46	5.93	7.56	1.41	2.02	(3.12)	2.44	5.70	7.10
	Diluted :	1.30	1.87	(3.35)	2.32	5.57	7.11	1.33	1.91	(3.12)	2.30	5.36	6.67

Note : The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and on the Company's website (www.gokaldasexports.com).

By order of the Board of Directors  
 For Gokaldas Exports Ltd.  
 Sd/-  
**Sivaramakrishnan Vilayur Ganapathi**  
 Managing Director  
 DIN : 07954560

Place: Bengaluru  
 Date: January 29, 2021

**ROYAL INDIA CORPORATION LIMITED**  
 CIN No. L45400MH1964PLC032274,  
 Tel No. 022-43417777,  
 Fax No. 022-2287 7272,  
 E-mail: info@rcil.in, Website: www.rcil.in  
 Regd. Off: 62, 6th Floor, C Wing, Mittal Tower,  
 Nariman Point, Mumbai, Maharashtra 400021.

**NOTICE**  
 Notice is hereby given pursuant to Regulations 29 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), that the Meeting of the Board of Directors of the Company will be held on Thursday, February 04, 2021, at 02.00 p.m. inter alia, to consider and take on record the Unaudited Financial Results along with the Interim Review Report for the quarter ended December 31, 2020. Also, the trading window as per the Clause 4 of Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for prevention of Insider Trading will remain close with continuation from January 01, 2021 and will re-open 48 hours after the declaration of financial results.

The said information may be accessed on the Company's website at www.rcil.in and may also be accessed on the Stock Exchange website at www.bseindia.com.

For Royal India Corporation Limited  
 Sd/-  
 (Mr. Nitin Gujral)  
 DIN-08184605  
 Managing Director  
 Place: Mumbai  
 Date: January 29, 2021

**CFS Camlin Fine Sciences**  
**CAMLIN FINE SCIENCES LIMITED**  
 CIN: L74100MH1993PLC075361  
 Regd. Off.: Plot No: F/11 & F/12, WICEL,  
 Opp. SEEPZ Main Gate, Central Road,  
 Andheri (E), Mumbai - 400 093  
 Tel: +91-22-67001000; Fax: 28324404  
 Email: secretarial@camlins.com  
 Website: www.camlins.com

**NOTICE**  
 Notice is hereby given that, Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Monday, 8th February, 2021 to, inter-alia consider, take on record and approve the standalone and consolidated unaudited financial results for the third quarter ended 31st December, 2020.

The trading window of the Company for dealing in the equity shares has been closed from 1st January, 2021 and shall re-open 48 hours after the declaration of financial results for the quarter ended 31st December, 2020.

This Notice is also available on the website of the Company at www.camlins.com and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

For Camlin Fine Sciences Limited  
 Sd/-  
 Mandar Godbole  
 Company Secretary &  
 General Manager Legal  
 Place: Mumbai  
 Date : 29th January, 2021

**HOME LOAN**  
**6.90%**  
 Onwards  
**Loan upto ₹ 15cr**

► 6 EMI Waiver on Ready to Move Home  
 ► Exclusive Griha Varishtha Home Loan scheme for retired pensioners and salaried individuals having pension benefit with loan tenure upto attainment of 80 years of age  
 ► Waiver of Processing Fees

**27.93%** Disbursement YoY (Q-3)  
**30.10%** PBT YoY (Q-3)  
**21.67%** PAT YoY (Q-3)

**LIC HFL**  
 LIC HOUSING FINANCE LTD  
 CIN: L65922MH1989PLC052257  
 Registered Office: Bombay Life Building, 2nd Floor,  
 45/47, Veer Nariman Road, Mumbai-400001,  
 Tel: +91-22-22049919, 22049799, Fax: +91-22-22049682  
 Corporate Office: 131 Maker Tower, "F" Premises,  
 13th Floor, Cuffe Parade, Mumbai-400005,  
 Tel: +91-22-22178600, Fax: +91-22-22178777  
 Email: lichousing@lichousing.com

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31/12/2020**  
 (₹ in Crore)

Sr. No.	Particulars	Quarter ended December 31, 2020	Nine Months ended December 31, 2020	Quarter ended December 31, 2019
		Reviewed	Reviewed	Reviewed
1	Total Income from Operations	4,923.99	14,883.32	4,996.47
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	969.64	2,996.57	745.32
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	969.64	2,996.57	745.32
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	727.04	2,335.42	597.53
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	721.37	2,329.13	595.55
6	Paid up Equity Share Capital	100.93	100.93	100.93
7	Earning Per Share (of ₹ 2/- each) (for continuing and discontinued operations) Basic & Diluted *(The EPS for the quarter & nine months ended is not annualised)	14.41*	46.28*	11.84*

**Notes**  
 1 The figures for the previous periods have been regrouped / reclassified / restated wherever necessary in order to make them comparable with figures for the current period ended December 31, 2020.  
 2 The above is an extract of the detailed format of Quarterly/ Nine months ended Standalone Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full format of the Quarterly / Nine months ended Standalone Financial Results are available on the Stock Exchanges - National Stock Exchange (NSE), Bombay Stock Exchange(BSE) websites www.nseindia.com , www.bseindia.com and Company's website www.lichousing.com.

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31/12/2020**  
 (₹ in Crore)

Sr. No.	Particulars	Quarter ended December 31, 2020	Nine Months ended December 31, 2020	Quarter ended December 31, 2019
		Reviewed	Reviewed	Reviewed
1	Total Income from Operations	4,926.65	14,900.31	5,006.02
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	970.08	3,002.66	751.36
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	970.08	3,002.66	751.36
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	721.11	2,334.86	602.25
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	713.69	2,330.08	600.25
6	Paid up Equity Share Capital	100.93	100.93	100.93
7	Earning Per Share (of ₹ 2/- each) (for continuing and discontinued operations) Basic & Diluted *(The EPS for the Quarter and Nine Months ended is not annualised)	14.29*	46.27*	11.93*

**Notes**  
 1 The figures for the previous periods have been regrouped / reclassified / restated wherever necessary in order to make them comparable with figures for the current period ended December 31, 2020.  
 2 The above is an extract of the detailed format of Quarterly/Nine months ended Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full format of the Annual Standalone and Consolidated Financial Results are available on the Stock Exchanges - National Stock Exchange (NSE), Bombay Stock Exchange(BSE) websites www.nseindia.com , www.bseindia.com and Company's website www.lichousing.com.

For and on behalf of the Board  
 Sd/-  
**Siddhartha Mohanty**  
 Managing Director & CEO

Place : Mumbai  
 Date : January 29, 2021

financialxp.in

Apply online at lichousing.com







